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ApoptosisDeoxyribose-phosphate aldolase (EC 4.1.2.4), which converts 2-deoxy-D-ribose-5-phosphate into glyceraldehyde-
3-phosphate and acetaldehyde, belongs to the core metabolism of living organisms. It was previously shown that
human cells harbor deoxyribose phosphate aldolase activity but the protein responsible of this activity has never
been formally identiﬁed. This study provides the ﬁrst experimental evidence that DERA, which is mainly expressed
in lung, liver and colon, is the human deoxyribose phosphate aldolase. Among human cell lines, the highest DERA
mRNA level and deoxyribose phosphate aldolase activity were observed in liver-derived Huh-7 cells. DERA was
shown to interact with the known stress granule component YBX1 and to be recruited to stress granules after
oxidative or mitochondrial stress. In addition, cells in which DERA expression was down-regulated using shRNA
formed fewer stress granules andweremore prone to apoptosis after clotrimazole stress, suggesting the importance
of DERA for stress granule formation. Furthermore, the expression of DERA was shown to permit cells in which
mitochondrial ATP production was abolished to make use of extracellular deoxyinosine to maintain ATP levels.
This study unraveled a previously undescribed pathway which may allow cells with high deoxyribose-phosphate
aldolase activity, such as liver cells, to minimize or delay stress-induced damage by producing energy through
deoxynucleoside degradation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Deoxyribose phosphate aldolase (EC 4.1.2.4) catalyzes the conver-
sion of 2-deoxy-D-ribose-5-phosphate (DR5P) into glyceraldehyde-3-
phosphate (G3P) and acetaldehyde [1]. DeoC is a Schiff-forming class I
aldolase, which is responsible for deoxyribose phosphate aldolase activ-
ity in bacteria [2,3]. It has been widely used as a biocatalyst to perform
stereo-controlled aldol condensation because of its ability to use various
aldehydes as substrates [4]. The resolution of the crystal structures of
Escherichia coli (E. coli) deoC (PDB: 1JCJ and 1JCL) [5,6] and of its
orthologs in Thermus thermophilus (PDB: 1UB3 and 1J2W) [7] and inxyribose-5-phosphate; DR1P,
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razone; PB, Processing bodies;
epartment of Human Protein
, 1211 Geneva 4, Switzerland.
iss Institute of Bioinformatics,
eneva, CMU, Michel-Servet 1,
lydie.lane@isb-sib.ch (L. Lane).the archae Aeropyrum pernix (PDB: 1N7K) [8] permitted identiﬁcation
of the lysine residues implicated in the Schiff base formation and engi-
neering of DeoCmutants with increased speciﬁcity for substrates useful
in industrial applications. Deoxyribose phosphate aldolase activity has
been detected in mammalian samples including liver [9–12], human
erythrocytes [13], and a variety of rat and human cells [12,14–16], but
the protein responsible for this activity in mammals has never been
formally identiﬁed. The mammalian enzyme shares some of its charac-
teristics with the bacterial ones, such as sensitivity to carboxylic acids
and to reducer agents [9,13].
Along with DeoA (thymidine phosphorylase, EC 2.4.2.4), DeoB
(phosphopentomutase, EC 5.4.2.7), and DeoD (purine nucleoside phos-
phorylase, EC 2.4.2.1), E. coliDeoC is part of the deo operonwhich allows
bacteria to use extracellular deoxynucleosides as energy sources [17]:
DeoD or DeoA cleaves the glycosidic bond of the deoxyribonucleoside
and liberates a deoxyribose-1-phosphate (DR1P) that is further con-
verted into DR5P by DeoB. Finally, DeoC converts DR5P into G3P and
acetaldehyde, which enter glycolysis and the Krebs cycle, respectively
[1]. Inmammalian cells a pathway involving TYMP (thymidine phosphor-
ylase) [18,19], PGM2 (phosphopentomutase) [20], and PNP (purine
nucleoside phosphorylase) [21,22] as functional equivalents of DeoA,
DeoB and DeoD, respectively, has been described (Fig. 1A). Known as
Fig. 1. The expression proﬁle of DERA, the DeoC ortholog, correlates with deoxyribose phosphate aldolase activity in human cells. (A) Enzymes implicated in the catabolism of the
deoxyribose moiety of thymidine in E. coli and human. (B) Alignment of E. coli DeoC (P0A6L0), T. kodakaraensis DeoC (Q877I0) and human DERA (Q9Y315). The lysines essential
for DeoC activity are shown in bold. (C, D) DERA expression values measured by qRT-PCR on human tissues (representative experiment) (C) and cell lines (means ± s.d., n = 3)
(D). (E) Deoxyribose phosphate aldolase activity values in cell lines (means ± s.d., n = 3).
2914 L. Salleron et al. / Biochimica et Biophysica Acta 1843 (2014) 2913–2925the nucleoside salvage pathway, it allows cells to maintain a balanced
pool of deoxynucleosides. However, it is still unclearwhether inmamma-
lian cells DR5P can be further converted into energy derivatives [23].
In this study, we show that DERA is the mammalian deoxyribose
phosphate aldolase, and that this enzyme confers on cells the ability
to use deoxynucleosides to replenish ATP cellular levels upon stress.We report that DERA interacts with YBX1, a protein involved in DNA
repair, and that, similar to YBX1 [24], it is recruited to stress granules
(SG) upon different kinds of stress. SG are cytoplasmic bodies which
formwhen the cell is exposed to adverse conditions in order to prevent
apoptosis and preserve cell viability [25]. We show also that DERA is
necessary for SG formation and prevention of apoptosis after stress.
2915L. Salleron et al. / Biochimica et Biophysica Acta 1843 (2014) 2913–29252. Material and methods
2.1. Sequence analysis
The putative human ortholog for the DERA enzymes from E. coli
(P0A6L0) and Thermococcus kodakaraensis (Q877I0) was searched by
BLASTP analysis in the UniProtKB database version 15.14 [26]. Multiple
sequence alignments were performed using Clustal Omega with the
default parameters [27].2.2. Cell culture
All cellswere grown in an incubator at 37 °C in a 5% CO2 atmosphere.
HEK293, Huh-7, HepG2, Caco-2 and HeLa Kyoto cells were grown in
DMEM (Life Technologies) supplemented with 10% fetal bovine
serum (Sigma-Aldrich). Jurkat cells were grown in RPMI 1640 (Life
Technologies) supplemented with 10% fetal bovine serum. Treatments
with clotrimazole, sodium arsenite, cycloheximide (CHX) (Sigma-
Aldrich) and carbonyl cyanide-4-(triﬂuoromethoxy)phenylhydrazone
(FCCP) (Enzo Life Sciences) were done at 37 °C for the indicated time.
Sodium arsenite was used at 0.12 mM unless otherwise noted. Clotri-
mazole and FCCP were dissolved in DMSO and used at 20 μM and
10 μM respectively. CHX was dissolved in DMEM without serum (Life
Technologies) and used at 20 μg/ml.2.3. qRT-PCR
cDNA from cells was prepared from 500 ng RNA extracted
with RNeasy kit (Qiagen), using superscript II reverse transcriptase
(Life technologies). Tissue cDNAs were from Clontech. qRT-PCR reac-
tions were performed in triplicates using 5′-CAAGGCTGCAGGCTGT
AATA-3′ and 5′-CATCTTCCACAGCCAATCTG-3′ as primers and the
Power SYBR Green PCR Master mix (Applied Biosystems). Raw
cycle threshold values were obtained with SDS 2.2.2 (Applied
Biosystems). Normalization by TBP expression was performed
using GeNorm [28].2.4. Plasmids and transfection
siRNA against YBX1 and silencer select negative control (40 nM, Life
Technologies) were transfected using lipofectamine RNAiMAX (Life
Technologies) in serum-freemedia 24h before treatmentwith stress in-
ducers. Plasmid transfections were performed using XtremeGene-HP
(Roche). pDEST-mycYBX1 was from Addgene (plasmid 19878) [29].
DERA cDNA was ampliﬁed from HeLa cells by PCR using 5′-CACCTCCG
CGCACAATCGGGGCAC-3′ and 5′-CACCTCCGCGCACAATCGGGGCAC-3′
as primers, cloned in pENTR-D-TOPO, then in pDEST15 or in
pcDNA3.1/nv5 using the Gateway cloning kit (Life Technologies).
DERA-6xHis sequence was obtained by PCR performed on pENTR-D-
TOPO-DERA vector using CGT-GAA-AAG-CTT-ATG-TCC-GCG-CAC-AAT-
CGG-GGC-ACC-GA and TAG-CAC-TAG-TTC-ATT-AGT-GGT-GGT-GGT-
GGT-GGT-GGT-GGT-GGC as primers, and inserted in pEAK8 [30]
digested with HindIII and EcoRI. K218A and K254A DERA-6xHis mu-
tants were obtained by overlap extension PCR [31]. The expression of
DERA-6XHis and its mutants in PEAK cells was checked by Western
blot using anti-His (1:2000; Abd serotec) and anti-β-catenin (1:2000;
Sigma-Aldrich) antibodies. Transient DERA downregulation was done
by transfection of the pRNAi-H1-puro plasmid containing the shRNA
sequence AAA-ACC-ATC-ATG-TGA-CTG-GAA-GAT-ATT-GGA-TCC-AAT-
ATC-TTC-CAG-TCA-CAT-GAT-GG targeting DERA coding sequence.
HeLa cell clones stably expressing DERA shRNA were selected using
1 μg/ml puromycin. The lacZ shRNA pRNAi vector (Biosettia) was used
as control.2.5. Imaging
Cells were ﬁxed with 4% paraformaldehyde, permeabilized and
blocked with 3% BSA in PBS with 0.25% Triton X-100, and incubated
with primary antibodies (rabbit anti-DERA (1:50, Epitomics), rabbit
anti-YBX1 (1:50, HPA040304, gift from M. Uhlen), goat anti-G3BP1
(1:50, Santa Cruz), goat anti-DCP1A (1:50, Santa Cruz), goat anti-c-
Myc (1:200, AbD Serotec), or mouse anti-PABPC1 (1:50, Santa Cruz).
For immunoﬂuorescence experiments, secondary antibodies were don-
key anti-IgG coupled to Alexa Fluor (1:150, Life Technologies). Nuclei
were stainedwith 4′,6-diamidino-2-phenylindole (DAPI) (moutingme-
dium, Prolong, Life Technologies). Confocal ﬂuorescence images were
obtained using an Axio Imager M2 microscope with a 63× oil objective
and the ZEN software (Carl Zeiss). Images were compiled using Adobe
Photoshop software (Adobe Systems). Scale bars are 10 μm in images
and 2 μm in inserts.
2.6. Stress granule counting
SG were counted using the “analyze particles” tool of the ImageJ
software (NIH), with a SG area set to 0.7–78 μm2 [32], and all countings
were manually checked. A minimum of 100 cells from duplicate cover-
slips were counted for each experiment.
2.7. In situ proximity ligation assay
The in situ proximity ligation assay was performed on
paraformaldehyde-ﬁxed cells according to manufacturer's instruction
(Olink Bioscience) using either anti-DERA (1:50) and anti c-Myc
(1:200) or anti-v5 (1:200) (Life Technologies) and anti-YBX1 (1:50)
as primary antibodies, and secondary antibodies coupled to Texas Red
labeled oligonucleotides (1:40, Olink Bioscience). The secondary anti-
bodies are linked with complementary labeled oligonucleotides that
interact when they are in close proximity (less than 40 nm). Each
interacting pair is ampliﬁed with a polymerase and visualized as a
distinct spot.
2.8. Deoxyribose phosphate aldolase assay
Deoxyribose phosphate aldolase activity was assayed by spectro-
photometry using the alcohol dehydrogenase (ADH)-coupled method
[33] on cells lysed in RIPA buffer (150 mM NaCl, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0), 2% Triton X-100, with
protease and phosphatase inhibitors (Complete; Roche). Assay was
performed at 37 °C in phosphate citrate buffer pH 6.8 with 4 mg of
total proteins, 2 mM DR5P (gift from P.-A. Kaminski), 500 × 10−3 U
Saccharomyces cerevisiae ADH (Sigma-Aldrich) and 0.4 M NADH
(Sigma-Aldrich). One unit of enzyme activity catalyzes the formation
of 1 μmol of product/min.
2.9. ATP measurements
Cellular ATP concentrations were determined according to
manufacturer's instructions (ATP Bioluminescence Assay Kit HS II,
Roche Applied Science) following cell incubation for 2 h with 10 μM
FCCP in DMEM without glucose (Life Technologies), in presence of
8 mM inosine (Sigma-Aldrich) or 8 mM deoxyinosine (Sigma-Aldrich).
Luminescence was monitored in a plate-reader luminometer (Fluostar
Optima, BMG Labtechnologies).
2.10. Detection of apoptosis by annexin V staining
Cells were stained with annexin V-APC (Allophycocyanin) and
propidium iodide (PI) in binding buffer (PBS, 2 mM CaCl2) according
to manufacturer's instructions (BD Biosciences), and analyzed using
an Accury C6 ﬂow cytometer (BD Biosciences). We considered both
2916 L. Salleron et al. / Biochimica et Biophysica Acta 1843 (2014) 2913–2925cells in early apoptosis thatwere annexin Vpositive andPI negative, and
cells in late apoptosis that were annexin V positive and PI positive.2.11. Statistics
Data are shown as means ± standard deviation (s.d.) of results
from at least three independent experiments, or ± standard error
of themean (s.e.m.) of results frommore than three independent exper-
iments. Statistical analysis was done by performing Student's t test (star
marks in the ﬁgure legends: *p b 0.05, **p b 0.01, ***p b 0.001).2.12. GST pull-down
Competent BL21(DE3)pLysS cells (Agilent) were transformed with
pDEST15-DERA or pGEX3t4-GST (a gift from P. Viollier). Protein expres-
sionwas inducedwith 0.5mM isopropyl-β-D-thiogalactoside (IPTG) for
16 h at 18 °C. Bacteria were lysed in extraction buffer (50 mM Tris
pH 7.8, 300 mM NaCl, 5 mM MgCl2, 10 mM 2-mercaptoethanol, 2%
Triton X-100, with protease inhibitors (Complete, Roche) and 1 mg/ml
lysozyme) and sonicated. After centrifugation, the supernatants
containing the recombinant proteins were incubated with glutathione–
sepharose (Sigma-Aldrich). GST or GST-DERA beads were washed and
incubated with HeLa proteins (1.5 mg) extracted with RIPA buffer.
When indicated, lysates were treated with 500 units DNAse I or
4 μg RNAse A for 1 h at 37 °C. Bound proteins were eluted with
Laemmli buffer (2% SDS, 10% glycerol, 5% 2-mercaptoethanol,
0.125 M Tris HCl pH 6.8), and analyzed by Western blot using anti-
YBX1 (1:1000). For mass spectrometry analysis, bound proteins
were concentrated in a stacking SDS-PAGE gel, stained with
Coomassie, excised and digested with trypsin. Peptides were submitted
to liquid chromatography–tandem mass spectrometry (LC-MS/MS)
using a LTQ Orbitrap velos (Thermo Electron) equipped with a
NanoAcquity system (Waters). Peptide identiﬁcation was performed
using Mascot (Matrix Sciences) on Homo sapiens UniProtKB/Swiss-
Prot sequences (release 15.10). Scaffold_4.2.0 (Proteome Software
Inc., Portland, OR) was used to validate identiﬁcations. Peptide and
protein identiﬁcations were accepted if they could be established at
greater than 95.0% probability by Peptide Prophet and Protein Prophet,
respectively [34]. Proteins with less than two unique tryptic peptides
were discarded.2.13. His pull-down
HeLa cells co-transfected with pDERA and pDEST-c-Myc-YBX1were
lysed in RIPA buffer with 10 mM 2-mercaptoethanol, 2% Triton X100
and incubated with Ni-NTA afﬁnity matrix (Qiagen) for 2 h at 4 °C.
Bound proteins were eluted with Laemmli buffer, and analyzed by
Western blot using anti c-Myc (1:1000).2.14. Co-immunoprecipitation
HeLa cells co-transfected with pDERA and pDEST-MycYBX1 were
lysed in RIPA buffer with 2% TX-100, for 15 min at 4 °C then cell de-
bris were removed by centrifugation. The supernatant containing the
solubilized proteins (5 mg) was incubated for 1 h at 4 °C with anti c-
Myc (30 μg) antibody. Subsequently, protein G agarose (GE
Healthcare) was added (50 μl of 50% slurry), and the incubation
was continued for an additional 1 h at 4 °C. The protein G agarose
was washed three times with PBS with 0.2% Tween and bound pro-
teins were then eluted with Laemmli buffer. Samples were analyzed
by SDS-PAGE and immunoblotting using anti-YBX1 (1/1000) and
anti-DERA (1/500).3. Results
3.1. DERA is the human deoxyribose phosphate aldolase.
By BLAST analysis, DERA appeared to be the ortholog of bacterial and
archaeal DeoC, sharing 38% identity with E. coli DeoC and 22% identity
with T. kodakaraensis DeoC. Furthermore, the two lysines essential for
E. coli DeoC activity [6] are conserved in DERA (K218 and K254)
(Fig. 1B). By qRT-PCR, the highest expression of DERA was observed in
liver, lung and colon among human tissues (Fig. 1C), and in hepatocellu-
lar carcinoma Huh-7 cells and colorectal adenocarcinoma Caco-2
cells among cell lines of various origins (Fig. 1D). As expected, the
highest deoxyribose phosphate aldolase activity was observed in
hepatocarcinoma Huh-7 (0.47 × 10−3 ± 0.05 U/mg), Jurkat T
lymphocyte-derived cells and hepatoblastoma HepG2 cells showed
moderate activities (0.18 × 10−3 ± 0.06 U/mg and 0.15 × 10−3 ±
0.03 U/mg, respectively) (Fig. 1E).
In order to conﬁrm that DERA can act as a deoxyribose phosphate
aldolase, DERA-6xHis or its putative catalytic mutants (K218A; K254A
and K218A/K254A) were overexpressed in HeLa cells. To this end,
DERA-6xHis cDNA was cloned into pEAK8, to yield a bicistronic vector
(pDERA) which permits high DERA-6xHis expression and easy detection
of transfected cells which express GFP (Fig. 2A). pDERA-K218A, pDERA-
K254A and pDERA-K218A/K254A constructs were generated by overlap
extension PCR. As expected, HeLa cells transfected with increasing
concentrations of pDERA showed increasing levels of DERA-6xHis
(Fig. 2B) and increasing deoxyribose phosphate aldolase activity levels
(0.150 × 10−3 ± 0.001 U/mg with 10 μg pDERA; 0.284 × 10−3 ± 0.02
U/mg with 25 μg pDERA and 0.304 × 10−3 ± 0.03 U/mg with 30 μg
pDERA), although the levels obtained by DERA-6xHis overexpression do
not reach those found endogenously in hepatocarcinoma Huh-7 cells
(0.470 × 10−3 ± 0.05 U/mg) (Fig. 1E). In contrast, HeLa cells transfected
with 10 μg pDERA mutants did not show any increase in deoxyribose
phosphate aldolase activity compared to cells transfected with 10 μg
empty pEAK8 vector (0.091 × 10−3 ± 0.017 U/mg for empty vector
versus 0.113 × 10−3 ± 0.01 U/mg for pDERA-K218A/K254A; 0.123 × 10
−3 ± 0.005 U/mg for pDERA-K218A; 0.105 × 10−3 ± 0.003 U/mg for
pDERA-K254A) (Fig. 2C), which conﬁrms that K218 and K254 are re-
quired for DERA activity.
Next, to conﬁrm that the deoxyribose phosphate aldolase activity
measured in untransfected cells was contributed by endogenous
DERA, we monitored deoxyribose phosphate aldolase activity in HeLa
cell lines that stably downregulate DERA by expressing short hairpin
RNA (shRNA) targeting its coding sequence. By immunoﬂuorescence
with a speciﬁc DERA antibody and by qRT-PCR, we checked that
these cells display lower levels of DERA protein and mRNA than
control cells expressing shRNA-LacZ (Fig. 2D and E). DERA shRNA cells
had 75% lower aldolase activity than control shRNA cells (Fig. 2F),
which conﬁrmed that DERA is the human deoxyribose phosphate
aldolase.
3.2. DERA interacts with YBX1
In order to elucidate DERA's physiological function, we attempted to
ﬁnd its potential interacting partners by pull down experiments.
Recombinant GST-DERA produced in bacteria (Fig. 3A) was used as
bait to perform pull down experiments on HeLa cell lysates and GST
was used as a control for speciﬁcity. Fifty-six proteins were identiﬁed
by mass spectrometry (MS) in the GST-DERA but not in the GST pull-
down eluates. Among those, we excluded proteins that bound to other
unrelated GST fusion proteins, and abundant contaminant proteins
usually recovered using this method, including keratins and keratin-
associated proteins. Finally, we obtained a list of 15 proteins which
speciﬁcally bind to GST-DERA (Supplementary Table 1). Based on the
fact that DR5P, the substrate of DERA, can come from deoxynucleotide
catabolism or from base excision repair of damaged DNA, we
Fig. 2. DERA is responsible for deoxyribose phosphate aldolase activity in mammalian cells. (A) Schematic representation of the different elements of the bi-cistronic pEAK8-DERA
(pDERA): elongation factor 1 alpha (EF-1) promoter, DERA-6xHis, internal ribosome entry site (IRES) and GFP. (B, C) HeLa cells were transiently transfected with various amounts of
pDERA or with 10 μg of pDERA mutants. (B) Western blot analysis conﬁrmed expression of the different constructs. (C) The bar graph shows means ± s.d. of deoxyribose phosphate
aldolase activity values measured in three independent experiments. (D) HeLa cells stably expressing control and DERA shRNA were ﬁxed and immunostained for DERA. Nuclei were
visualized by DAPI. Scale bars are 10 μm. (E) DERA downregulation in HeLa cells stably expressing DERA shRNA was checked by qRT-PCR. The bar graph shows means ± s.d. of values
obtained in three independent experiments. (F) Deoxyribose phosphate aldolase activity is severely decreased in DERA shRNA cells. The bar graph shows means ± s.d. of deoxyribose
phosphate aldolase activity values measured in three independent experiments.
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identiﬁed by three unique peptides with 24% sequence coverage
(Fig. 3B), for further validation.We conﬁrmed the YBX1 MS identiﬁcation result by Western blot
analysis using anti-YBX1 antibody (Fig. 3C). Since YBX1 is involved
in transcription, translation, alternative splicing regulation and DNA
Fig. 3.DERA interacts with YBX1 in stressed and unstressed cells. (A) Coomassie Blue-stained SDS-PAGE gel showing GST-DERA and GST immobilized on glutathione sepharose. (B) GST-
DERA and GST immobilized on glutathione sepharose were used as baits for pull-down experiments on HeLa protein lysates and partners were identiﬁed by LC-MS/MS analysis of the
eluates. YBX1 was identiﬁed by three unique peptides covering 24% of YBX1 sequence, from four spectra validated manually. (C) GST-DERA or GST beads (20 μg) were incubated with
HeLa lysates treated or not with DNAse I or RNAse A. The presence of YBX1 in eluates and inputs (10%) was analyzed by Western blot with anti-YBX1. (D). HeLa cells transfected with
c-Myc-YBX1 (left panel) or v5-DERA (right panel) were either untreated or treated with 20 μM clotrimazole (Clo) or 0.5 mM arsenite (As), then subjected to in situ proximity ligation
assay using anti-DERA and anti-c-Myc (left panel) or anti-v5 and anti-YBX1 antibodies (right panel). Untransfected cells were used as negative control. Each dot represents the two
proteins in close proximity. Scale bars are 10 μm. (E) HeLa cells were transfected with pDERA or pDERA-K218A/K254A and c-Myc-YBX1 and treated with clotrimazole. Cell lysates
were incubated with nickel afﬁnity columns to pull DERA-6xHis down. The presence of c-Myc-YBX1 and DERA-6xHis was analyzed by Western blot in pull down eluates (PD) and
input samples (10%) using anti-c-Myc and anti-His. (F) c-Myc-YBX1 and DERA-6xHis were co-immunoprecipitated from HeLa cell lysates transfected with pDERA and c-Myc-YBX1. As
controls we used untransfected cells or cells transfected with c-Myc-YBX1 alone.
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2919L. Salleron et al. / Biochimica et Biophysica Acta 1843 (2014) 2913–2925repair, and has the ability to bind DNA and RNA [38,39], we checked that
YBX1 was able to bind GST-DERA even when lysates were treated with
DNAse or RNAse, thus excluding that DNA or RNA could mediate this
interaction (Fig. 3C).
YBX1 is a known component of SG [24,40]. SG are cytoplasmic bod-
ies formed upon translational arrest in response to environmental
stresses such as sodium arsenite (oxidative stress) or clotrimazole
(mitochondrial stress) [25]. To visualize the interaction between YBX1
and DERA in unstressed conditions and in conditions promoting SG
formation, we performed in situ proximity ligation assays [41] on
c-Myc-YBX1-transfected HeLa cells using anti-c-Myc and anti-DERA
antibodies and on v5-DERA-transfected cells using anti-v5 and anti-
YBX1 antibodies. Endogenous DERA was found in proximity (b40 nm)
to c-Myc-YBX1, both in unstressed cells and in stressed cells treated
with sodium arsenite or clotrimazole (Fig. 3D, left panel). Similarly, en-
dogenous YBX1 was found in close proximity to v5-DERA in the same
conditions. In contrast, negligible non-speciﬁc binding of the probes
was observed in non-transfected cells. The interaction between YBX1
and DERA in clotrimazole-stressed HeLa cells was conﬁrmed by
His-pull down experiments in cells overexpressing c-Myc-YBX1 and
DERA-6xHis (Fig. 3E). c-Myc-YBX1 was able to bind DERA-K218A/
K254A-6xHis as well (Fig. 3E), indicating that DERA catalytic residues
are not involved in this interaction. To further conﬁrm the interaction
between DERA and YBX1, we carried out co-immunoprecipitation
experiments on untreated HeLa cells transfected with c-Myc-YBX1
and pDERA. DERA-6X-His was successfully co-immunoprecipitated
with c-Myc-YBX1 using an anti-c-Myc antibody (Fig. 3F).
3.3. DERA is localized in stress granules but not in processing bodies
Because the interaction between DERA and YBX1 takes place both in
unstressed and stressed cells, we investigated DERA localization by
immunoﬂuorescence in both conditions. DERA is localized both in the
nucleus and the cytoplasm in unstressed HeLa cells (Figs. 2D and 4A),
consistently with its suggested role in nucleotide metabolism. This
localization is compatiblewith that of YBX1,which is cytosolic in resting
cells (Fig. 4A), but can shuttle between cytoplasm and nucleus in
speciﬁc conditions such as UV treatment [42], or upon interaction
with the splicing factor SRp30c [43].
Upon exposure to arsenite or clotrimazole, DERA was detected in
the same cytoplasmic granules as c-Myc-YBX1. These granules were
identiﬁed as SG using G3BP1 [44] and PABPC1 [45] as markers. DERA
also localized to H2O2-induced SG together with G3BP1 and PABP
(data not shown). We checked that c-Myc-YBX1 has the same localiza-
tion as endogenous YBX1 in each condition (Fig. 4). Similar results were
obtained in Jurkat, Huh-7 and HepG2 cells (data not shown).
SG assembly requires polysome disassembly and the subsequent
release of mRNAs, which are recruited by RNA-binding proteins which
form the core of SG. As a consequence, cycloheximide (CHX),whichpre-
vents polysome disassembly, impairs SG formation [46]. CHX added at
the same time as arsenite or clotrimazole totally prevented the forma-
tion of DERA, c-Myc-YBX1, G3BP1 and PABPC1 foci (Fig. 4B). Therefore,
polysome disruption is required for DERA incorporation into SG. CHX
has also been shown to disassemble pre-formed SG [46]. After clotrima-
zole stress, CHX completely disassembled DERA and G3BP1-containing
SG, and partially disassembled c-Myc-YBX1- and PABPC1-containing
SG. After arsenite stress, the effect of CHXwasmilder, sincewe observed
only a partial dissolution of DERA-containing SG and no change in the
other markers (Fig. 4C). These results suggest that DERA, G3BP1,
c-Myc-YBX1- and PABPC1 have different SG exit kinetics, and that
DERA may be the ﬁrst marker to exit SG.
Processing bodies (PB) are cytoplasmic granules, distinct from SG,
where mRNA decay takes place. They contain proteins involved in
mRNA decapping, such as DCP1A, and proteins involved in mRNA
degradation [47]. PB are always present in the cell, but their size and
number grow upon arsenite treatment [48], and many proteins andmRNAs contained in SG can shuttle to PB during stress [25,49].
However, using DCP1A as a marker, we observed that, upon arsenite
treatment, DERA and YBX1 are not incorporated into PB (Fig. 4C).
Altogether, these results show that, in our conditions, endogenous
DERA and YBX1 are associated with SG but not with PB.
Because DERA contains neither a typical RNA-binding motif, nor a
glycine or glutamine rich C-terminal tail known to be involved in SG
targeting [40], we studied if DERA interaction with YBX1 could be
important for its localization to SG. We analyzed DERA localization
after arsenite stress in HeLa cells in which YBX1 levels were downregu-
lated using siRNA. The diminution in YBX1 protein level was checked by
Western blot (Fig. 5A). SG containing PABPC1, G3BP1 and DERA could
still be observed in these conditions (Fig. 5B), suggesting that YBX1 is
not required for the formation of SG in these conditions, nor for DERA
targeting to SG. However, the low levels of YBX1 remaining after
siRNA treatment might be sufﬁcient to ensure proper SG formation
and DERA targeting to SG.
3.4. DERA is important for stress granule formation
In order to know if DERA plays a role in SG assembly, we analyzed
the effect of DERA depletion on SG formation in HeLa cells. We used
transient rather than stable shRNA interference to make sure that the
observed phenotype was not due to clonal effects of the stable cell
lines. In HeLa cells expressing DERA shRNA, we observed a four-fold
decrease in DERA mRNA measured by qRT-PCR (Fig. 6A), and a
concomitant diminution in the number of G3BP1-containing and
YBX1-containing SG formed during clotrimazole stress compared to
cells expressing control LacZ shRNA (Fig. 6B and C). Fewer G3BP1- and
YBX1-containing SG were also formed during arsenite stress (Fig. 6D).
In contrast, DCP1A-containing PB observed upon arsenite stress do not
seem to be affected by DERA depletion (Fig. 6E). These results highlight
the importance of DERA in SG formation, but not in PB formation.
SG are known to be a major adaptive response of cells to stress, by
preventing them from undergoing apoptosis. For example, sequestra-
tion of activated ROCK1 in SG prevents its association with TRAF3IP3,
and, thus, prevents apoptosis [50]. Therefore, we tested whether cells
downregulating DERA were more prone to apoptosis during clotrima-
zole stress. Indeed, we observed a 35% increase in apoptosis visualized
with annexin V staining in cells expressing low level of DERA compared
to cells transfected with control shRNA (Fig. 6F).
3.5. DERA activity may allow cells to use deoxyinosine as an energy source
Arsenite and clotrimazole trigger SG assembly through activation of
kinases causing the phosphorylation of the translation initiation factor
eIF2α, a component of the eIF2-GTP-Met-tRNAMet complex. On the
other hand, drugs that deplete intracellular energy stores, such as the
mitochondrial uncoupler FCCP, cause SG assembly independent of
eIF2α phosphorylation, by reducing the ATP/ADP ratio, which leads to
a decrease in the GTP/GDP ratio and hence to a reduced formation of
the eIF2-GTP-Met-tRNAMet complex [25]. As described above, DERA is
recruited to arsenite- or clotrimazole-induced SG (Fig. 4). To know if
DERA is also recruited to SG upon energy depletion, we applied a
combination of glucose deprivation and FCCP toHeLa cells. In these con-
ditions, ATP levels drop (Fig. 7C) and cells form SG containing YBX1,
PABPC1 and G3BP1 (Fig. 7A). Importantly, DERA is also recruited to SG
in this context (Fig. 7A).
In bacteria, DeoB and DeoC allow cells to use the pentose moiety of
deoxynucleosides present in their growth medium as an energy source
[17,51]. In human, extracellular deoxynucleosides can come from nutri-
tional sources, or be released from cells into the circulation.Mammalian
PGM2 [20], PNP [21] and DERA are functional homologues of bacterial
DeoB, DeoD and DeoC. However, it is still not known if the phosphory-
lated pentose released by phosphorolytic cleavage of deoxynucleosides
in human can be catabolized by DERA and used as a source of energy in
Fig. 4.DERA is recruited to stress granules (SG) but not to processing bodies (PB). (A–C) Left panels: c-Myc-YBX1-transfected HeLa cells were exposed to 0.12mM arsenite (As) or 20 μM
clotrimazole (Clo)with orwithout 20 μg/ml cycloheximide (CHX),ﬁxed and immunostained for DERA (red) and c-Myc-YBX1, G3BP1 or PABPC1 (green). Right panels: UntransfectedHeLa
cells were exposed to 0.12 mM arsenite (As) or 20 μM clotrimazole (Clo) with or without 20 μg/ml cycloheximide (CHX), ﬁxed and immunostained for YBX1 (red) and G3BP1 (green).
(A) DERA co-localized with SG components after arsenite or clotrimazole stress. (B) CHX added at the same time as clotrimazole or arsenite blocks SG formation. (C) DERA-containing
SG are totally disassembled when CHX is added after clotrimazole and partially disassembled when CHX is added after arsenite. (D) Untransfected HeLa cells were exposed to
0.12 mM arsenite, ﬁxed and immunostained for DCP1A (green) and DERA or YBX1 (red). DERA and YBX1 granules cluster around DCP1A-containing PB in As-treated cells. Scale bars
are 10 μm in images and 2 μm in inserts. Merge color is yellow.
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Fig. 5. YBX1 knockdown does not impair DERA recruitment to stress granules in HeLa cells. HeLa cells were transiently transfected with control siRNA or YBX1 siRNA for 24 h. (A) YBX1
expression was checked byWestern blot using anti-YBX1 and anti-α-tubulin as loading control. (B) Cells were treated with 0.5 mM arsenite for 1 h, ﬁxed and immunostained for DERA
(red) and G3BP1 or PABPC1 (green). Merge color is yellow. Scale bars are 10 μm.
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hypothesis was that mammalian cells could use deoxyinosine as
an energy source, through the action of PNP, PGM2 and DERA.
Deoxyinosine, which can be produced endogenously by deamination
of deoxyadenosine by the adenosine deaminase enzyme (ADA), would
be cleaved by PNP into hypoxanthine and DR1Pwhich would be subse-
quently isomerized by PGM2 to DR5P [23]. Then, DR5P would be used
by DERA to produce G3P that would enter the glycolysis pathway, and
acetaldehyde that would enter the Krebs cycle so as to produce ATP.
Therefore, we tested whether DERA could allow ATP production from
extracellular deoxyinosine in conditions of energy deprivation. We
started our investigation with Huh-7 cells, which express high levels
of DERA. After 2 h incubation with FCCP in the absence of glucose, ATP
levels were less than 10% of those of control cells. The addition of extra-
cellular inosine (from 0.5 mM to 8 mM) prevented the ATP drop, prob-
ably through the action of PNP, which produces ribose-5-phosphate
that can enter the pentose phosphate pathway. More importantly,
deoxyinosine (from 0.5 mM to 8 mM) also prevented the ATP drop
(Fig. 7B), indicating that Huh-7 cells are able to catabolize deoxyinosine
into energy derivatives.
We repeated the experiment in HeLa cells, which express low levels
of DERA. In these cells, the addition of extracellular inosine prevented
the ATP drop that occurs in the presence of FCCP, but not the addition
of deoxyinosine at a concentration which signiﬁcantly helps in ATP
preservation in Huh-7 cells (8 mM) (Fig. 7C). We hypothesized that
this was due to insufﬁcient endogenous deoxyribose phosphate
aldolase activity, as previously suggested for other cell lines [16,23].
Thus, we tested if increasing the deoxyribose phosphate aldolase activ-
ity in HeLa cells would allow them to use deoxyinosine to overcome the
stress induced by energy deprivation. To this end, we used HeLa cells
transfected with wild type or mutant pDERA. HeLa cells overexpressing
wild-type DERA restored their ATP levels in the presence of 8 mM
deoxyinosine, whereas cells overexpressing DERA catalytic mutant did
not (Fig. 7C). Then, we tested if the number of SG correlates with ATP
depletion in cells transfected with wild type or mutant pDERA and
incubated with extracellular inosine or deoxyinosine. In the presence
of extracellular inosine, fewer SG are formed in cells transfected with
wild type or mutant pDERA (Fig. 7D) conﬁrming that these cells can
use inosine as a source of energy. In the presence of extracellular
deoxyinosine, cells transfected with wild type pDERA formed fewer
SG, whereas cells transfected with mutant pDERA formed the same
number of SG (Fig. 7D), conﬁrming that only cells overexpressing a
catalytically active deoxyribose phosphate aldolase were able to use
deoxyinosine as a source of energy upon stress.
4. Discussion
In this study, we measured a signiﬁcant deoxyribose phosphate
aldolase activity in various human cell lines, with the highest levels
found in hepatocarcinoma Huh-7 cells, hepatoblastoma HepG2 cellsand Jurkat T lymphocyte-derived cells. In contrast to previous reports
stating that deoxyribose phosphate aldolase activity levels vary among
samples due to extractability and stability issues [1,11], we noted low
enzyme activity variability among our samples. Also, even if the condi-
tions we used to measure DERA activity were different from that of
other studies, the activity levels we measured are in the range of what
was previously reported for mammalian samples [12,13,16]. Although
bacterial and mammalian deoxyribose phosphate aldolase were
shown to be both activated by carboxylic acids and reducing agents
[9,11], the speciﬁc activities reported for the mammalian enzymes are
much lower than the bacterial ones. Indeed, the highest mammalian
activity (6 × 10−3 U/mg), measured in rat liver [12], is far below the
lowest activity in bacteria (0.97 U/mg), measured in Bacillus cereus
[52]. This may explain why the mammalian enzyme had attracted
such poor attention.
Using both up- and downregulation of DERA expression in HeLa
cells, we demonstrated that DERA is responsible for the human deoxy-
ribose phosphate aldolase activity, and identiﬁed two lysines implicated
in its catalytic activity, conﬁrming that it is a class I aldolase [6].
Among human tissues, the highest DERA expression levels were
found in the liver, where most of the early studies on the mammalian
deoxyribose phosphate aldolase were performed [10,53,54]. Liver cells
contain a high deoxynucleotide/nucleotide ratio compared to other
cell types [55]. They incorporate alimentary extracellular nucleosides
which can further be phosphorylated and reduced to deoxynucleotides
[56,57]. It is also themain site of nucleobase recycling during the degra-
dation of deoxynucleotides. Degradation of deoxynucleotides generates
DR5P and is regulated by the need for free bases by other cells and by
the abundance of nucleosides provided by food absorption [55]. Nota-
bly, DNPH1, which produces DR5P directly from deoxynucleotides, is
also highly expressed in the liver [58,59]. Therefore, one can expect
that the liver would contain high levels of DERA's substrate. DERA is
also well expressed in lung and in colon, where (deoxy)nucleosides
originating from inhalated or symbiotic microorganisms can accumu-
late and be reduced to deoxynucleotides, fromwhich catabolism gener-
ates DR5P [60]. Accordingly, the highest DERA expression levels in cell
lines were observed in liver Huh-7 and colon Caco-2 cells. Our panel
did not include lung cancer cell lines, where we would have expected
high levels of DERA expression as well.
We found that deoxyribose phosphate aldolase activity levels corre-
late with DERA expression level in most cell lines. Indeed, we found a
high deoxyribose phosphate aldolase activity in Huh-7 cells, intermedi-
ate activities in HepG2 and Jurkat cells, and low activities in HeLa and
HEK293 cells. The only discrepancy that we noticed was for Caco-2
cells, which display a low deoxyribose phosphate aldolase activity,
despite high DERA mRNA levels. This result is in accordance with
another study reporting that colon carcinoma LoVo cells do not display
any detectable activity [23]. The unexpectedly low deoxyribose
phosphate aldolase activity observed in colon cancer cell lines may be
due to speciﬁc post-translational events, such as phosphorylation.
Fig. 6. DERA knockdown prevents assembly of stress granules in HeLa cells. HeLa cells were transiently transfected with control shRNA and shRNA targeting DERA coding sequence for
48 h. (A) DERA expression levels measured by qRT-PCR (n= 2). (B, C) HeLa cells were transiently transfected with control shRNA or DERA shRNA, and treated for 1 h with clotrimazole
(Clo), ﬁxed and immunostained for DERA, G3BP1 and YBX1. Scale bars are 10 μm. The bar graph (C) showsmeans± s.e.m. of the number of G3BP1 and YBX1-containing SG analyzed in a
minimum of 100 cells from duplicate coverslips. The number of YBX1 and G3BP1-containing stress granules per cell is decreased in cells down-regulating DERA. (D, E) HeLa cells were
transiently transfected with control shRNA or DERA shRNA, and treated for 1 h with 0.5 mM arsenite (As), ﬁxed and immunostained for DERA or YBX1 (red) and G3BP1 or DCP1A
(green), as indicated. Merge color is yellow. Scale bars are 10 μm in images and 2 μm in inserts. DERA depletion reduces the number of SG (D) but does not affect DCP1A localization
(E) after arsenite treatment. (F) DERA depletion increases the percentage of apoptotic cells stained with annexin V after 1 h clotrimazole treatment. The bar graph shows means ±
s.e.m. in eight independent experiments.
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creases its activity [61]. The corresponding position in human DERA,
Thr292, was shown to be a possible target for Polo-like kinase 1
(PLK1) [62], which is overexpressed in a majority of cancer cells.
Furthermore, we cannot exclude that DERA protein amounts could be
modulated at the levels of protein translation and/or degradation.
Such mechanisms have been recently highlighted to explain the fre-
quently observed lack of correlation between the cellular concentration
of a protein and its mRNA abundance [63]. Our preliminary studiesusing the TargetScan tool (http://www.targetscan.org/) predict that
the 3′-UTR of DERA could be targeted by hsa-miR-4766-3p, but the
presence of this miRNA in colon cells still needs to be investigated.
We highlighted that cells with high DERA activity can use
deoxynucleosides as a source of energy. Indeed, Huh-7 cells endoge-
nously expressing high DERA levels and HeLa cells overexpressing
DERA can use extracellular deoxyinosine to recover the ATP pool
depleted by FCCP in the absence of glucose. In contrast, cells with low
DERA levels, such as wild-type HeLa cells, can convert inosine into ATP
Fig. 7. Cells with high deoxyribose phosphate aldolase activity can use deoxyinosine to preserve ATP levels during metabolic stress. Cells were either left in glucose-containing media
(untreated), or grown in a medium without glucose in the presence or absence of FCCP, and incubated with deoxyinosine or inosine for 2 h. (A) HeLa cells were treated as indicated,
ﬁxed and immunostained for DERA or YBX1 (red) and PABPC1 (green). Scale bars are 10 μm in images and 2 μm in inserts. Merge color is yellow. HeLa cells form SG containing DERA,
PABPC1 and YBX1 upon energy starvation. (B) ATP levels in Huh-7 cells grown with different concentrations of deoxyinosine or inosine (means ± s.d. values, n = 3). (C) ATP levels in
HeLa cells transfected with empty vector, pDERA or pDERA-K218A/K254A (means ± s.d. values, n = 3). (D) Number of G3BP1-containing SG per cell after transfection of HeLa cells
with pDERA (black bars) or pDERA-K218A/K254A (dashed bars) and the indicated treatment (means ± s.e.m. of n N 100 cells from duplicate coverslips). DERA overexpression allows
cells to overcome clotrimazole-induced stress.
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previously shown in other cells [16]. Interestingly, the liver where we
found a high expression of DERA has a high requirement for protein
synthesis [64] and therefore needs high levels of energy that DERA
may help supporting.
We observed that endogenous DERA is both cytoplasmic and
nuclear, as expected from its role in deoxynucleotide metabolism.
More surprisingly, DERA was found to be recruited to SG upon energy
starvation, oxidative stress or mitochondrial stress. SG assembly is a
major defensive mechanism that the cell puts in place to avoid apopto-
sis and increase its viability [50]. For example, in erythroid cells that
form spontaneous SG, a 60% increase in apoptosis occurswhen SG forma-
tion is impaired by down-regulation of the core SG protein G3BP1 [65]. In
addition to mRNA and core mRNA-binding proteins, SG sequester pro-
apoptotic proteins such as ROCK1 [50] aswell as small ribosomal subunits
to prevent translation reinitiating [25], and contain proteins that allow
quick cell recovery once the stress is over and SG are disassembled,
such as HNRNPA1 [66], CASC3 [67] or DDX3X [68]. Also, DERA may help
cells to recover energy after stress, by catabolizing the DR5P released
through deoxynucleotide degradation. In line with this hypothesis, we
showed that DERA downregulation in HeLa cells decreased the number
of clotrimazole- and arsenite-induced SG, and signiﬁcantly increased
the percentage of apoptotic cells following clotrimazole stress.
We showed that DERA was able to bind YBX1 in unstressed condi-
tions and under SG-promoting stresses. While YBX1 is known to be
targeted to SG via its ‘cold-shock’ RNA-binding domain [69], DERA has
no putative SG-targeting domain and how it is targeted to SG remains
unclear. Our results using siRNA against YBX1 indicate that YBX1 isdispensable for arsenite-induced SG formation and for DERA localiza-
tion in SG, but we cannot exclude that the little amount of YBX1 left in
the cells after siRNA treatmentwould be sufﬁcient tomediate both pro-
cesses. Indeed, YBX1 knockdown reduces the number of SG induced by
tRNA cleavage, which suggests that it has a role in their assembly [70]. It
is still unclear whether DERA acts in SG assembly through its enzymatic
activity, or through its interactionwith YBX1. To test these two possibil-
ities, one should try to rescue the SG formation defects observed in cells
downregulating DERA by overexpressing either wild type DERA or its
catalytically inactive mutant, which can still bind YBX1. However, this
experiment is difﬁcult to perform sincewe observed that the extracellu-
lar addition of DNA plasmids to cells downregulating DERA causes cell
death, as it was shown for the addition of exogenous DNA to DeoC-
deﬁcient bacteria [17].
Beside its localization in SG upon stress, YBX1 is a cytoplasmic
protein that can shuttle to the nucleus upon speciﬁc conditions, and
bind to apurinic DNA sites [71], which are among the most frequent
hallmarks of DNA damage. It has been shown that stresses that induce
SG, such as arsenite, induce high levels of apurinic/apyrimidic DNA
damage products [72], and that SG assembly helps in the establishment
of the DNA damage response [73]. In addition, proteins involved in DNA
repair, such as poly [ADP-ribose] polymerases, localize in SG and are
essential for SG assembly [74,75], although their mechanism of action
is still unclear. Since DERA was found both in SG and in the nucleus,
its possible role in DNA repair in association with YBX1 would merit
further investigation.
Looking for proteins inﬂuencing SG assembly, Ohn and colleagues
identiﬁed 131 proteins involved in various biological processes
2924 L. Salleron et al. / Biochimica et Biophysica Acta 1843 (2014) 2913–2925including transcription, protein modiﬁcation, DNA repair or fructose
metabolism [75]. Since then, several studies have expanded that list,
but the precise role of each protein in SG assembly is not fully under-
stood. Our study adds DERA to this list and shows that it interacts
with YBX1, which is involved both in DNA repair and SG formation,
thus providing unexpected links between deoxynucleotidemetabolism,
DNA repair and SG assembly pathways.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.09.007.
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